Phytotherapy's Impact on Immune Regulation in Degenerative Diseases
DOI:
https://doi.org/10.58511/jnpdd.v3i1.9261Keywords:
Phytotherapy, Immune Regulation, Degenerative Diseases, Inflammation, PhytochemicalsAbstract
This literature review looks at how phytotherapy affects immune regulation in degenerative diseases like neurodegenerative, autoimmune, and metabolic disorders. We begin by outlining a theoretical framework that explains how chronic inflammation, caused by pathways such as NF-κB and the NLRP3 inflammasome, plays a central role in these conditions. Next, we explore how different phytochemicals, including flavonoids, stilbenes, and phenolic acids, achieve their therapeutic effects by influencing these important inflammatory pathways, lowering cytokine production, and offering antioxidant support. The review applies this knowledge to specific diseases, emphasizing how compounds like curcumin and resveratrol may help reduce neuroinflammation and improve immune balance. Finally, we discuss the main challenges related to bioavailability and standardization, suggesting future research paths to realize the full potential of these natural compounds as effective strategies for managing chronic degenerative conditions.
References
[1] W. C. Chong et al., “The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders,” Clin & Trans Imm, vol. 10, no. 2, Jan. 2021, doi: 10.1002/cti2.1247.
[2] H. Kang, “MicroRNA-Mediated Health-Promoting Effects of Phytochemicals,” IJMS, vol. 20, no. 10, p. 2535, May 2019, doi: 10.3390/ijms20102535.
[3] K. Gąsiorowski, G. E. Barreto, V. Echeverria, J. Leszek, and B. Brokos, “RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration.,” Mol Neurobiol, vol. 55, no. 2, pp. 1463–1476, Feb. 2017, doi: 10.1007/s12035-017-0419-4.
[4] G. Kannan, B. M. Paul, and P. Thangaraj, “Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review.,” Inflammopharmacol, vol. 33, no. 1, pp. 145–162, Jan. 2025, doi: 10.1007/s10787-024-01635-4.
[5] M. A. Samad et al., “STAT3 Signaling Pathway in Health and Disease.,” MedComm, vol. 6, no. 4, Mar. 2025, doi: 10.1002/mco2.70152.
[6] C. Paget, E. Doz-Deblauwe, N. Winter, and B. Briard, “Specific NLRP3 Inflammasome Assembling and Regulation in Neutrophils: Relevance in Inflammatory and Infectious Diseases,” Cells, vol. 11, no. 7, p. 1188, Apr. 2022, doi: 10.3390/cells11071188.
[7] M. Latos‐Brozio and A. Masek, “Structure-Activity Relationships Analysis of Monomeric and Polymeric Polyphenols (Quercetin, Rutin and Catechin) Obtained by Various Polymerization Methods.,” Chemistry & Biodiversity, vol. 16, no. 12, Nov. 2019, doi: 10.1002/cbdv.201900426.
[8] Radeva and K. Yoncheva, “Resveratrol-A Promising Therapeutic Agent with Problematic Properties.,” Pharmaceutics, vol. 17, no. 1, p. 134, Jan. 2025, doi: 10.3390/pharmaceutics17010134.
[9] D. K. Khatri and A. R. Juvekar, “Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid,” Phcog Mag, vol. 12, no. Suppl 2, p. 116, May 2016, doi: 10.4103/0973-1296.182168.
[10] Z. Qiao, H. Hu, X. Yuan, B. Yan, S. Shi, and L. Chen, “An Update on the Function, Biosynthesis and Regulation of Floral Volatile Terpenoids,” Horticulturae, vol. 7, no. 11, p. 451, Nov. 2021, doi: 10.3390/horticulturae7110451.
[11] D. Cox-Georgian, C. Dona, N. Ramadoss, and C. Basu, “Therapeutic and Medicinal Uses of Terpenes,” vol. 3, no. 5, Springer, 2019, pp. 333–359. doi: 10.1007/978-3-030-31269-5_15.
[12] Y. Xiong and J. Huang, “Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment,” Chin Med, vol. 16, no. 1, Aug. 2021, doi: 10.1186/s13020-021-00489-0.
[13] C. Caliceti, A. F.G Cicero, S. Spinozzi, P. Franco, and A. Roda, “Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders,” CMC, vol. 23, no. 14, pp. 1460–1476, May 2016, doi: 10.2174/0929867323666160411143314.
[14] B. Balakrishnan et al., “Combining the Anticancer and Immunomodulatory Effects of Astragalus and Shiitake as an Integrated Therapeutic Approach,” Nutrients, vol. 13, no. 8, p. 2564, July 2021, doi: 10.3390/nu13082564.
[15] A. Mobasheri, Y. Henrotin, H.-K. Biesalski, and M. Shakibaei, “Scientific Evidence and Rationale for the Development of Curcumin and Resveratrol as Nutraceutricals for Joint Health,” IJMS, vol. 13, no. 4, pp. 4202–4232, Mar. 2012, doi: 10.3390/ijms13044202.
[16] R. Duggleby, R. D. Danby, J. A. Madrigal, and A. Saudemont, “Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies,” Front. Immunol., vol. 9, no. 2, Feb. 2018, doi: 10.3389/fimmu.2018.00252.
[17] M. A. Islam, M. A. Kamal, S. H. Gan, M. Solayman, M. I. Khalil, and F. Alam, “Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases.,” Oxidative Medicine and Cellular Longevity, vol. 2016, no. 48, pp. 1–25, Jan. 2016, doi: 10.1155/2016/5137431.
[18] V. Zoi, V. Galani, G. D. Lianos, S. Voulgaris, A. P. Kyritsis, and G. A. Alexiou, “The Role of Curcumin in Cancer Treatment,” Biomedicines, vol. 9, no. 9, p. 1086, Aug. 2021, doi: 10.3390/biomedicines9091086.
[19] S. Mohammadian Haftcheshmeh, A. Mohammadi, A. Khosrojerdi, S. Lotfi, A. Aliabadi, and A. A. Momtazi-Borojeni, “Immunomodulatory Effects of Curcumin in Rheumatoid Arthritis: Evidence from Molecular Mechanisms to Clinical Outcomes.,” Reviews of physiology, biochemistry and pharmacology, vol. 179, pp. 1–29, Jan. 2020, doi: 10.1007/112_2020_54.
[20] Y.-P. Chang et al., “Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy.,” J. Cell. Physiol., vol. 230, no. 7, pp. 1567–1579, Mar. 2015, doi: 10.1002/jcp.24903.
[21] J. Mlcek, J. Sochor, T. Jurikova, and S. Skrovankova, “Quercetin and Its Anti-Allergic Immune Response.,” Molecules, vol. 21, no. 5, p. 623, May 2016, doi: 10.3390/molecules21050623.
[22] Y. Wang et al., “The Effects of Berberine on Concanavalin A-Induced Autoimmune Hepatitis (AIH) in Mice and the Adenosine 5’-Monophosphate (AMP)-Activated Protein Kinase (AMPK) Pathway.,” Med Sci Monit, vol. 23, pp. 6150–6161, Dec. 2017, doi: 10.12659/msm.907377.
[23] L. Müller and S. Di Benedetto, “Neuroimmune crosstalk in chronic neuroinflammation: microglial interactions and immune modulation,” Front. Cell. Neurosci., vol. 19, Apr. 2025, doi: 10.3389/fncel.2025.1575022.
[24] S. M. Awad et al., “Efficacy of curcumin-selenium nanoemulsion in alleviating oxidative damage induced by aluminum chloride in a rat model of Alzheimer’s disease.,” J Mol Histol, vol. 56, no. 2, Mar. 2025, doi: 10.1007/s10735-025-10406-6.
[25] C.-Y. Cheng et al., “Epigallocatechin-3-Gallate-Loaded Liposomes Favor Anti-Inflammation of Microglia Cells and Promote Neuroprotection.,” IJMS, vol. 22, no. 6, p. 3037, Mar. 2021, doi: 10.3390/ijms22063037.
[26] P. Luo et al., “Immunomodulatory role of T helper cells in rheumatoid arthritis,” Bone & Joint Research, vol. 11, no. 7, pp. 426–438, July 2022, doi: 10.1302/2046-3758.117.bjr-2021-0594.r1.
[27] Y. Xu and L. Liu, “Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-κB signaling pathway.,” Influenza Resp Viruses, vol. 11, no. 5, pp. 457–463, July 2017, doi: 10.1111/irv.12459.
[28] M. Tang et al., “Pharmacological Aspects of Natural Quercetin in Rheumatoid Arthritis,” DDDT, vol. 16, no. 10055, pp. 2043–2053, June 2022, doi: 10.2147/dddt.s364759.
[29] Q. Ma et al., “Reshaping the Inflammatory Environment in Rheumatoid Arthritis Joints by Targeting Delivery of Berberine with Platelet‐Derived Extracellular Vesicles,” Advanced NanoBiomed Research, vol. 1, no. 11, p. 2100071, Aug. 2021, doi: 10.1002/anbr.202100071.
[30] A. Kuryłowicz and K. Koźniewski, “Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes,” Molecules, vol. 25, no. 9, p. 2224, May 2020, doi: 10.3390/molecules25092224.
[31] M. Hoca, E. Becer, and H. S. Vatansever, “The role of resveratrol in diabetes and obesity associated with insulin resistance,” Archives of Physiology and Biochemistry, vol. 129, no. 2, pp. 555–561, Mar. 2021, doi: 10.1080/13813455.2021.1893338.
[32] R. H. X. Wong and P. R. C. Howe, “Resveratrol Counteracts Insulin Resistance—Potential Role of the Circulation,” Nutrients, vol. 10, no. 9, p. 1160, Aug. 2018, doi: 10.3390/nu10091160.
[33] S. Qin et al., “AMPK and its Activator Berberine in the Treatment of Neurodegenerative Diseases.,” CPD, vol. 26, no. 39, pp. 5054–5066, May 2020, doi: 10.2174/1381612826666200523172334.
[34] M. Garcia‐Alloza, B. J. Bacskai, L. A. Borrelli, B. T. Hyman, and A. Rozkalne, “Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model,” Journal of Neurochemistry, vol. 102, no. 4, pp. 1095–1104, Mar. 2007, doi: 10.1111/j.1471-4159.2007.04613.x.
[35] X. Zhu, C. Wu, S. Qiu, X. Yuan, and L. Li, “Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis,” Nutr Metab (Lond), vol. 14, no. 1, Sept. 2017, doi: 10.1186/s12986-017-0217-z.
[36] B. Zhang et al., “Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3.,” Endocrine, vol. 62, no. 3, pp. 576–587, Aug. 2018, doi: 10.1007/s12020-018-1689-y.
[37] S.-I. Sohn et al., “Biomedical Applications and Bioavailability of Curcumin—An Updated Overview,” Pharmaceutics, vol. 13, no. 12, p. 2102, Dec. 2021, doi: 10.3390/pharmaceutics13122102.
[38] S.-I. Sohn et al., “Biomedical Applications and Bioavailability of Curcumin—An Updated Overview,” Pharmaceutics, vol. 13, no. 12, p. 2102, Dec. 2021, doi: 10.3390/pharmaceutics13122102.
